Acadia Pharmaceuticals Inc.
ACADAcadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. It is known for its flagship product, Nuplazid (pimavanserin), approved for the treatment of Parkinson's disease psychosis. The company's research and development efforts aim to address unmet medical needs in areas such as schizophrenia, dementia-related psychosis, and other neuropsychiatric conditions.
Company News
Acadia Pharmaceuticals shares surged 12.2% after the European Medicines Agency's Committee recommended approval of Daybue for Rett syndrome treatment in the EU. The company, which focuses on rare neurological and psychiatric disorders, is profitable with two approved drugs generating significant revenue. While the European market for Rett syndrom...
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.
The Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.
The global neuroregeneration therapy market is expected to grow significantly, driven by advancements in regenerative medicine and the rising prevalence of neurological disorders. Key players are investing heavily in R&D, leading to innovative therapies and clinical trials that are accelerating market expansion.
